Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Fevipiprant Once Daily Plus Standard-of-care (SoC) for Assessment of the Efficacy in Reduction of Nasal Polyp Size in Patients With Nasal Polyposis and Concomitant Asthma

Trial Profile

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Fevipiprant Once Daily Plus Standard-of-care (SoC) for Assessment of the Efficacy in Reduction of Nasal Polyp Size in Patients With Nasal Polyposis and Concomitant Asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fevipiprant (Primary) ; Mometasone
  • Indications Asthma; Nasal polyps
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms THUNDER
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 27 Jan 2022 Primary endpoint (Change From Baseline in Nasal Polyp Score at Week 16) has not been met, as per results published in the Journal of Allergy and Clinical Immunology
  • 27 Jan 2022 Results published in the Journal of Allergy and Clinical Immunology
  • 14 Nov 2020 This trial is completed in Netherlands and Italy according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top